Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Clin Cancer Res. 2016 Nov 1;22(21):5177-5182. doi: 10.1158/1078-0432.CCR-16-1415. Epub 2016 Sep 8.
Over the last 2 years, our therapeutic armamentarium against genomically defined subgroups of non-small cell lung cancer (NSCLC) has extended to patients with acquired resistance to front-line targeted therapy. Alectinib (Alecensa; Roche/Genentech), a second-generation, orally active, potent, and highly selective inhibitor of anaplastic lymphoma kinase (ALK), is indicated for patients with metastatic, ALK rearrangement-positive NSCLC whose disease has worsened after treatment with crizotinib or who became intolerant to the drug. Alectinib received orphan drug designation, breakthrough therapy designation, priority review status, and accelerated approval by the FDA. Clin Cancer Res; 22(21); 5177-82. ©2016 AACR.
在过去的 2 年中，我们针对非小细胞肺癌（NSCLC）的基因组定义亚组的治疗武器已经扩展到对一线靶向治疗产生获得性耐药的患者。艾乐替尼（Alecensa；罗氏/基因泰克）是第二代、口服、有效、高度选择性的间变性淋巴瘤激酶（ALK）抑制剂，适用于接受克唑替尼治疗后疾病进展或对该药物不耐受的转移性、ALK 重排阳性 NSCLC 患者。艾乐替尼获得了孤儿药、突破性治疗药物、优先审查和 FDA 加速批准的认定。临床癌症研究；22(21)；5177-82。©2016AACR。
